Should I Buy SKYE? SKYE 2026 Analysis

Should You Buy Skye Bioscience Inc (SKYE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.960

1 Day change

-4.95%

52 Week Range

5.750

Analysis Updated At

2026/01/26

Skye Bioscience Inc (SKYE) is not a strong buy for a beginner, long-term investor at this moment. The technical indicators are neutral, options data suggests bearish sentiment, and the news highlights significant legal risks. Additionally, the company's financial performance is weak, with no revenue and substantial losses. While there is a potential positive catalyst with the upcoming Keystone conference, the risks outweigh the benefits for a beginner investor with a long-term focus.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 54.246, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 1.008, with resistance at 1.071 and support at 0.945. Overall, the technical indicators suggest a neutral trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The low open interest put-call ratio indicates a lack of bullish sentiment, while the high option volume put-call ratio suggests bearish activity. Implied volatility is high at 233.7%, and the IV rank is low at 20.39, indicating limited upside potential.

Technical Summary

Sell

Buy

Positive Catalysts

The company will present its study on the obesity-targeting antibody nimacimab at the Keystone conference on January 28, 2026, which could generate positive sentiment if results are promising.

Neutral/Negative Catalysts

Two class action lawsuits alleging securities fraud and overstated efficacy of nimacimab are significant risks. These legal issues could negatively impact investor confidence and the stock price.

Financial Performance

In Q3 2025, the company reported no revenue, a net loss of $12,754,660 (up 227.19% YoY), and an EPS of -0.32 (up 220% YoY). While the YoY improvement in net income and EPS is notable, the lack of revenue and continued losses highlight weak financial health.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data is available for SKYE.

5 Analyst Rating

Wall Street analysts forecast SKYE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKYE is 14.33 USD with a low forecast of 10 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 1.010

Low

Averages

14.33

High

Current: 1.010

Low

Averages

14.33

High

H.C. Wainwright

Ananda Ghosh

Buy

initiated

$20

AI Analysis

2025-09-30

Reason

H.C. Wainwright

Ananda Ghosh

Price Target

$20

AI Analysis

2025-09-30

initiated

Buy

Reason

H.C. Wainwright analyst Ananda Ghosh initiated coverage of Skye Bioscience with a Buy rating and $20 price target. The firm believes the company's nimacimab can introduce a new mechanism of longstanding interest to obesity clinicians. Nimacimab is a peripherally restricted monoclonal antibody targeting the CB1 receptor, designed to deliver the metabolic benefits of CB1 blockade without the psychiatric side effects that derailed earlier small molecule antagonists, the analyst tells investors in a research note. H.C. Wainwright views Sykes shares as undervalued at current levels.

Evercore ISI

Michael DiFiore

Outperform

initiated

$10

2025-08-14

Reason

Evercore ISI

Michael DiFiore

Price Target

$10

2025-08-14

initiated

Outperform

Reason

Evercore ISI analyst Michael DiFiore initiated coverage of Skye Bioscience with an Outperform rating and $10 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SKYE

Unlock Now

SKYE Should I Buy

SKYE Should I Buy

Should You Buy Skye Bioscience Inc (SKYE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch